RNS / HALF YEAR REPORT28 Oct 2022 08:52
Therefore, the total unaudited value of our unconsolidated investment portfolio as at 30 September 2022 is £5,128,000 (31 March 2022: £4,716,000)
Kirkstall's new Quasi Vivo™ product platform is in the final stages of user testing prior to market launch in December 2022. Its advanced fluid flow and compact design are considered highly desired by both pharmaceutical and academic users.
Kirkstall's partnership in the €4m European project CyGenTig is progressing well. The consortium is developing and testing new techniques to produce engineered tissues by optogenetics, with the aim to build replacement human organs by controlling individual cell growth and differentiation.
changed in recent months, the Company believes that demonstration of performance in a clinical setting will attract potential licensees and acquirers to Paraytec's CX300 technology platform, not only for point-of-care COVID-19 testing but for many other potential applications.
Cx300
As previously reported, the Paraytec team is progressing two further applications for the CX300 instrument; a Proof of Concept demonstration of a test for pathogens causing sepsis; and a method to analyse the quality of Virus Like Particles which are used in gene therapy medicine.
As previously reported, the Paraytec team is progressing two further applications for the CX300 instrument; a Proof of Concept demonstration of a test for pathogens causing sepsis; and a method to analyse the quality of Virus Like Particles which are used in gene therapy medicine.
Phasefocus,,,,, bigger sales
The Company will increase its marketing and direct sales activity in the EU and USA,
All in all looking sharpish...
More news soon on the cx300 needed before end of year..
Castle
Sign In
Follow the stocks
